Modra Pharmaceuticals Starts Phase 2 Trial of Oral Docetaxel in Metastatic Prostate Cancer

Modra Pharmaceuticals Starts Phase 2 Trial of Oral Docetaxel in Metastatic Prostate Cancer
Modra Pharmaceuticals has enrolled its first patient in a Phase 2 clinical trial (NCT03136640) of  ModraDoc006/r as a treatment for metastatic castration-resistant prostate cancer — an advanced and often fatal form of the disease ModraDoc006/r is a tablet formulation of docetaxel. Doctors administer it with the chemotherapy ritonavir to boost ritonavir’s bioavailablity, or amount that

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *